PURPOSE: Meningiomas and schwannomas associated with neurofibromatosis 2 (NF2) are difficult to control by microsurgery and stereotactic radiotherapy alone. Boron neutron capture therapy (BNCT) is a chemically targeted form of radiotherapy requiring increased concentration of boron-10 in tumour tissue. PET with the boron carrier 4-borono-2-[(18)F]fluoro-L-phenylalanine ([(18)F]FBPA) allows investigation of whether 4-borono-L-phenylalanine (BPA) concentrates in NF2 tumours, which would make BNCT feasible. METHODS: We studied dynamic uptake of [(18)F]FBPA in intracranial meningiomas (n=4) and schwannomas (n=6) of five sporadic and five NF2 patients. Tracer input function and cerebral blood volume were measured. [(18)F]FBPA uptake in tumour and brain was assessed with a three-compartmental model and graphical analysis. These, together with standardised uptake values (SUVs), were used to define tumour-to-brain [(18)F]FBPA tissue activity gradients. RESULTS: Model fits with three parameters K (1) (transport), k (2) (reverse transport) and k (3) (intracellular metabolism) were found to best illustrate [(18)F]FBPA uptake kinetics. Maximum SUV was two- to fourfold higher in tumour as compared with normal brain and independent of NF2 status. The increased uptake was due to higher transport of [(18)F]FBPA in tumour. In multiple-time graphical analysis (MTGA, Gjedde-Patlak plot) the tumour-to-brain [(18)F]FBPA influx constant (K (i) -MTGA) ratios varied between 1.8 and 5.4 in NF2-associated tumours while in sporadic tumours the ratio was 1-1.4. CONCLUSION: [(18)F]FBPA PET offers a viable means to evaluate BPA uptake in meningiomas and schwannomas in NF2. Based on our results on tumour uptake of [(18)F]FBPA, some of these benign neoplasms may be amenable to BNCT.
PURPOSE:Meningiomas and schwannomas associated with neurofibromatosis 2 (NF2) are difficult to control by microsurgery and stereotactic radiotherapy alone. Boron neutron capture therapy (BNCT) is a chemically targeted form of radiotherapy requiring increased concentration of boron-10 in tumour tissue. PET with the boron carrier 4-borono-2-[(18)F]fluoro-L-phenylalanine ([(18)F]FBPA) allows investigation of whether 4-borono-L-phenylalanine (BPA) concentrates in NF2 tumours, which would make BNCT feasible. METHODS: We studied dynamic uptake of [(18)F]FBPA in intracranial meningiomas (n=4) and schwannomas (n=6) of five sporadic and five NF2patients. Tracer input function and cerebral blood volume were measured. [(18)F]FBPA uptake in tumour and brain was assessed with a three-compartmental model and graphical analysis. These, together with standardised uptake values (SUVs), were used to define tumour-to-brain [(18)F]FBPA tissue activity gradients. RESULTS: Model fits with three parameters K (1) (transport), k (2) (reverse transport) and k (3) (intracellular metabolism) were found to best illustrate [(18)F]FBPA uptake kinetics. Maximum SUV was two- to fourfold higher in tumour as compared with normal brain and independent of NF2 status. The increased uptake was due to higher transport of [(18)F]FBPA in tumour. In multiple-time graphical analysis (MTGA, Gjedde-Patlak plot) the tumour-to-brain [(18)F]FBPA influx constant (K (i) -MTGA) ratios varied between 1.8 and 5.4 in NF2-associated tumours while in sporadic tumours the ratio was 1-1.4. CONCLUSION:[(18)F]FBPA PET offers a viable means to evaluate BPA uptake in meningiomas and schwannomas in NF2. Based on our results on tumour uptake of [(18)F]FBPA, some of these benign neoplasms may be amenable to BNCT.
Authors: Mauri Kouri; Leena Kankaanranta; Tiina Seppälä; Leena Tervo; Merja Rasilainen; Heikki Minn; Olli Eskola; Jyrki Vähätalo; Anders Paetau; Sauli Savolainen; Iiro Auterinen; Juha Jääskeläinen; Heikki Joensuu Journal: Radiother Oncol Date: 2004-07 Impact factor: 6.280
Authors: D H Gutmann; A Aylsworth; J C Carey; B Korf; J Marks; R E Pyeritz; A Rubenstein; D Viskochil Journal: JAMA Date: 1997-07-02 Impact factor: 56.272
Authors: G W Kabalka; G T Smith; J P Dyke; W S Reid; C P Longford; T G Roberts; N K Reddy; E Buonocore; K F Hübner Journal: J Nucl Med Date: 1997-11 Impact factor: 10.057
Authors: Y Mishima; C Honda; M Ichihashi; H Obara; J Hiratsuka; H Fukuda; H Karashima; T Kobayashi; K Kanda; K Yoshino Journal: Lancet Date: 1989-08-12 Impact factor: 79.321
Authors: K Ishiwata; M Shiono; K Kubota; K Yoshino; J Hatazawa; T Ido; C Honda; M Ichihashi; Y Mishima Journal: Melanoma Res Date: 1992-09 Impact factor: 3.599
Authors: G A Rouleau; P Merel; M Lutchman; M Sanson; J Zucman; C Marineau; K Hoang-Xuan; S Demczuk; C Desmaze; B Plougastel Journal: Nature Date: 1993-06-10 Impact factor: 49.962
Authors: Wolfgang A G Sauerwein; Lucie Sancey; Evamarie Hey-Hawkins; Martin Kellert; Luigi Panza; Daniela Imperio; Marcin Balcerzyk; Giovanna Rizzo; Elisa Scalco; Ken Herrmann; PierLuigi Mauri; Antonella De Palma; Andrea Wittig Journal: Life (Basel) Date: 2021-04-10